Cellectar Biosciences PE Ratio 2010-2024 | CLRB
Current and historical p/e ratio for Cellectar Biosciences (CLRB) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Cellectar Biosciences PE ratio as of May 05, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Cellectar Biosciences PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-05-06 | 0.24 | 0.00 | |
| 2024-12-31 | 0.30 | $-1.33 | 0.00 |
| 2024-09-30 | 2.14 | $-1.72 | 0.00 |
| 2024-06-30 | 2.50 | $-2.53 | 0.00 |
| 2024-03-31 | 3.98 | $-3.08 | 0.00 |
| 2023-12-31 | 2.77 | $-3.10 | 0.00 |
| 2023-09-30 | 2.64 | $-3.25 | 0.00 |
| 2023-06-30 | 1.95 | $-3.32 | 0.00 |
| 2023-03-31 | 1.43 | $-3.81 | 0.00 |
| 2022-12-31 | 1.71 | $-4.05 | 0.00 |
| 2022-09-30 | 3.36 | $-4.50 | 0.00 |
| 2022-06-30 | 4.04 | $-4.22 | 0.00 |
| 2022-03-31 | 6.88 | $-4.10 | 0.00 |
| 2021-12-31 | 6.64 | $-4.40 | 0.00 |
| 2021-09-30 | 9.25 | $-4.10 | 0.00 |
| 2021-06-30 | 11.90 | $-4.60 | 0.00 |
| 2021-03-31 | 16.10 | $-6.10 | 0.00 |
| 2020-12-31 | 20.80 | $-9.00 | 0.00 |
| 2020-09-30 | 12.40 | $-11.60 | 0.00 |
| 2020-06-30 | 12.80 | $-14.30 | 0.00 |
| 2020-03-31 | 13.33 | $-16.30 | 0.00 |
| 2019-12-31 | 22.50 | $-19.70 | 0.00 |
| 2019-09-30 | 20.00 | $-16.40 | 0.00 |
| 2019-06-30 | 21.80 | $-28.70 | 0.00 |
| 2019-03-31 | 23.50 | $-41.00 | 0.00 |
| 2018-12-31 | 15.50 | $-54.40 | 0.00 |
| 2018-09-30 | 30.00 | $-3,454.40 | 0.00 |
| 2018-06-30 | 62.00 | $-3,463.90 | 0.00 |
| 2018-03-31 | 113.50 | $-3,470.00 | 0.00 |
| 2017-12-31 | 137.00 | $-3,473.00 | 0.00 |
| 2017-09-30 | 167.00 | $-107.00 | 0.00 |
| 2017-06-30 | 163.00 | $-124.00 | 0.00 |
| 2017-03-31 | 227.00 | $-150.00 | 0.00 |
| 2016-12-31 | 122.00 | $-35.00 | 0.00 |
| 2016-09-30 | 271.00 | $-1.00 | 0.00 |
| 2016-06-30 | 344.00 | $-208.00 | 0.00 |
| 2016-03-31 | 341.83 | $-459.00 | 0.00 |
| 2015-12-31 | 735.00 | $-850.00 | 0.00 |
| 2015-09-30 | 1970.00 | $-1,070.00 | 0.00 |
| 2015-06-30 | 2880.00 | $-920.00 | 0.00 |
| 2015-03-31 | 3110.00 | $-1,350.00 | 0.00 |
| 2014-12-31 | 3090.00 | $-2,050.00 | 0.00 |
| 2014-09-30 | 2220.00 | $-3,230.00 | 0.00 |
| 2014-06-30 | 6390.00 | $-6,130.00 | 0.00 |
| 2014-03-31 | 7800.00 | $-6,200.00 | 0.00 |
| 2013-12-31 | 7400.00 | $-6,600.00 | 0.00 |
| 2013-09-30 | 7200.00 | $-6,200.00 | 0.00 |
| 2013-06-30 | 9200.00 | $-4,400.00 | 0.00 |
| 2013-03-31 | 9210.00 | $-4,800.00 | 0.00 |
| 2012-12-31 | 14800.00 | $-4,600.00 | 0.00 |
| 2012-09-30 | 21000.00 | $-4,800.00 | 0.00 |
| 2012-06-30 | 23800.00 | $-5,000.00 | 0.00 |
| 2012-03-31 | 17000.00 | $-5,800.00 | 0.00 |
| 2011-12-31 | 8800.00 | $-11,400.00 | 0.00 |
| 2011-09-30 | 25400.00 | $-11,800.00 | 0.00 |
| 2011-06-30 | 26000.00 | $-10,800.00 | 0.00 |
| 2011-03-31 | 54468.00 | $-70,338.45 | 0.00 |
| 2010-12-31 | 79254.00 | $-2,000.00 | 0.00 |
| 2010-09-30 | 159120.00 | $-800,399.90 | 0.00 |
| 2010-06-30 | 321300.00 | $-1,015,384.50 | 0.00 |
| 2010-03-31 | 556920.00 | $-1,353,846.05 | 0.00 |
| 2009-12-31 | 1000000.00 | $-1,630,769.10 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.012B | $0.000B |
| Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $230.702B | 27.74 |
| Boston Scientific (BSX) | United States | $154.217B | 38.61 |
| Stryker (SYK) | United States | $145.561B | 30.44 |
| EssilorLuxottica (ESLOY) | France | $133.244B | 0.00 |
| Medtronic (MDT) | Ireland | $107.028B | 15.63 |
| Lonza Group Ag (LZAGY) | Switzerland | $52.631B | 0.00 |
| Haleon (HLN) | United Kingdom | $47.943B | 27.26 |
| ResMed (RMD) | United States | $35.287B | 26.50 |
| GE HealthCare Technologies (GEHC) | United States | $31.763B | 15.08 |
| Agilent Technologies (A) | United States | $30.897B | 20.41 |
| Terumo (TRUMY) | Japan | $29.152B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $24.100B | 17.21 |
| Insulet (PODD) | United States | $18.209B | 77.71 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.901B | 11.50 |
| Baxter (BAX) | United States | $15.608B | 11.66 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.425B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $7.970B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $7.395B | 18.18 |
| Bio-Rad Laboratories (BIO) | United States | $6.728B | 22.75 |
| Prestige Consumer Healthcare (PBH) | United States | $4.111B | 19.62 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Perrigo (PRGO) | Ireland | $3.444B | 9.86 |
| ICU Medical (ICUI) | United States | $3.347B | 28.51 |
| Haemonetics (HAE) | United States | $3.139B | 14.77 |
| Envista Holdings (NVST) | United States | $2.876B | 23.90 |
| GN Store Nord (GNNDY) | Denmark | $2.071B | 17.15 |
| QuidelOrtho (QDEL) | United States | $1.868B | 15.64 |
| LeMaitre Vascular (LMAT) | United States | $1.817B | 40.63 |
| AtriCure (ATRC) | United States | $1.439B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.359B | 21.40 |
| Neogen (NEOG) | United States | $1.224B | 15.67 |
| AdaptHealth (AHCO) | United States | $1.173B | 11.30 |
| Kestra Medical Technologies (KMTS) | United States | $1.159B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.150B | 0.00 |
| InMode (INMD) | Israel | $0.991B | 9.08 |
| Phibro Animal Health (PAHC) | United States | $0.791B | 12.13 |
| Evolus (EOLS) | United States | $0.774B | 0.00 |
| Owens & Minor (OMI) | United States | $0.632B | 5.38 |
| Curaleaf Holdings (CURLF) | Canada | $0.618B | 0.00 |
| CeriBell (CBLL) | United States | $0.583B | 0.00 |
| Valneva SE (VALN) | France | $0.557B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.539B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.470B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.442B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.437B | 0.00 |
| Omeros (OMER) | United States | $0.397B | 0.00 |
| Surmodics (SRDX) | United States | $0.386B | 0.00 |
| SNDL (SNDL) | Canada | $0.355B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.348B | 15.09 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.312B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.290B | 26.18 |
| Sanara MedTech (SMTI) | United States | $0.288B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.265B | 47.20 |
| Sanuwave Health (SNWV) | United States | $0.265B | 0.00 |
| Cerus (CERS) | United States | $0.249B | 0.00 |
| ZimVie (ZIMV) | United States | $0.247B | 14.80 |
| Canopy Growth (CGC) | Canada | $0.234B | 0.00 |
| Quanterix (QTRX) | United States | $0.225B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.221B | 0.00 |
| High Tide (HITI) | Canada | $0.192B | 0.00 |
| Biote (BTMD) | United States | $0.178B | 4.06 |
| Utah Medical Products (UTMD) | United States | $0.172B | 13.83 |
| TriSalus Life Sciences (TLSI) | United States | $0.165B | 0.00 |
| Brainsway (BWAY) | Israel | $0.164B | 51.24 |
| Organigram Global (OGI) | Canada | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.145B | 17.91 |
| Jin Medical (ZJYL) | China | $0.125B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.118B | 0.00 |
| Exagen (XGN) | United States | $0.113B | 0.00 |
| Agape ATP (ATPC) | $0.105B | 0.00 | |
| MacroGenics (MGNX) | United States | $0.103B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.094B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.093B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.081B | 0.00 |
| Fonar (FONR) | United States | $0.076B | 10.61 |
| Veru (VERU) | United States | $0.075B | 0.00 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| Zynex (ZYXI) | United States | $0.064B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.057B | 0.00 |
| United Health Products (UEEC) | United States | $0.057B | 0.00 |
| ImmuCell (ICCC) | United States | $0.047B | 0.00 |
| Apyx Medical (APYX) | United States | $0.044B | 0.00 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.041B | 59.50 |
| Safety Shot (SHOT) | United States | $0.038B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 11.31 |
| Nephros (NEPH) | United States | $0.020B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.015B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.011B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.007B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |